文章摘要

莫沙必利联合抗Hp感染疗法对T2DM伴Hp阳性胃轻瘫患者血糖水平、胃肠功能和血清炎症因子的影响

作者: 1田巍巍, 2王琳
1 如皋市人民医院 消化内科,江苏 如皋 226500
2 如皋市人民医院检验科,江苏 如皋 226500
通讯: 田巍巍 Email: 805149904@qq.com
DOI: 10.3978/j.issn.2095-6959.2020.10.016

摘要

目的:探讨莫沙必利联合抗幽门螺杆菌(Helieobacter pylori,Hp)感染疗法对2型糖尿病(type 2 diabetes mellitus,T2DM)伴Hp阳性胃轻瘫患者血糖水平、胃肠功能以及血清炎症因子的影响。方法:选取2017年5月至2019年6月期间在如皋市人民医院门诊诊治的120例T2DM伴Hp阳性胃轻瘫患者,根据Excel生成的随机数分为对照组(n=60)和研究组(n=60),所有患者均严格控制血糖,对照组口服枸橼酸莫沙必利治疗,5 mg/次,每天3次;研究组在控制血糖和口服莫沙必利治疗基础上给予抗Hp感染疗法。治疗期间通过电话和门诊复查等保持随访,观察两组Hp根除率,并比较治疗前后空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2 hours postprandial blood glucose,2h PBG)、胃排空时间、胃泌素(gastrin,GAS)以及血清超敏C-反应蛋白(hypersensitive C-reactive protein,hs-CRP)、白介素-6(interleukin-6,IL-6)水平,评估两组胃轻瘫缓解疗效。结果:研究组Hp转阴率85.00%,高于对照组的13.33%(P<0.05);两组治疗后FBG,2h PBG,胃排空时间,GAS水平均有明显下降(P<0.05),且研究组治疗后上述指标均明显低于对照组,差异有统计学意义(P<0.05);对照组治疗前后血清hs-CRP,IL-6水平比较无显著差异(P>0.05),研究组hs-CRP,IL-6水平较治疗前均有明显下降(P<0.05),组间治疗后hs-CRP,IL-6水平比较,差异亦有统计学意义(P<0.05)。研究组胃轻瘫缓解总有效率96.67%,高于对照组的80.00%(P<0.05)。结论:莫沙必利联合抗Hp感染疗法能有效控制T2DM伴Hp阳性胃轻瘫患者血糖水平,改善胃肠功能和减轻血清炎症因子水平,提高胃轻瘫临床疗效。
关键词: 2型糖尿病;幽门螺杆菌;胃轻瘫;枸橼酸莫沙必利;抗Hp感染疗法;胃肠功能;炎症因子

Effect of Mosapride combined with anti HP infection therapy on blood glucose level, gastrointestinal function and serum inflammatory factors in T2DM patients with HP positive gastroparesis

Authors: 1TIAN Weiwei, 2WANG Lin
1 Department of Gastroenterology, Rugao People’s Hospital, Rugao Jiangsu 226500, China
2 Department of Clinical Laboratory, Rugao People’s Hospital, Rugao Jiangsu 226500, China

CorrespondingAuthor: TIAN Weiwei Email: 805149904@qq.com

Abstract

Objective: To investigate the effect of Mosapride combined with anti-Helicobacter pylori (HP) infection on blood glucose level, gastrointestinal function and serum inflammatory factors in type 2 diabetes mellitus (T2DM) patients with HP positive gastroparesis. Methods: From May 2017 to June 2019, 120 patients with T2DM and HP positive gastroparesis were randomly divided into a control group (n=60) and a study group (n=60) according to the random number generated by Microsoft Excel. All patients in the control group were strictly controlled by blood glucose. The control group was treated with mosapride citrate orally, 5 mg/time, 3 times/day. The study group was given anti HP infection therapy on the basis of controlling blood glucose and taking mosapride orally. During the treatment, the HP eradication rate of the two groups was observed by telephone and outpatient reexamination. The fasting blood glucose (FBG), 2 hours postprandial blood glucose (2 h PBG), gastric emptying time, gastrin (gas), and serum hypersensitive C-reactive protein (hs CRP) and interleukin-6 (IL-6) levels were compared before and after the treatment and measured to evaluate the relief effect of two groups of gastroparesis. Results: The negative rate of HP in the study group (85.00%) was higher than that in the control group (13.33%), (P<0.05); after the treatment, FBG, 2 h PBG, gastric emptying time, gas were significantly decreased in the 2 groups (P<0.05), and the above indexes in the study group were significantly lower than those in the control group (P<0.05); there was no significant difference in the levels of hs CRP and IL-6 in the control group before and after the treatment (P>0.05). The levels of hs CRP and IL-6 in the study group were significantly lower than those before the treatment (P<0.05). There was also significant difference in the levels of hs CRP and IL-6 between the 2 groups after the treatment (P<0.05). The total effective rate of relieving gastroparesis in the study group (96.67%) was higher than that in the control group (80.00%), (P<0.05). Conclusion: Mosapride combined with anti HP infection therapy can effectively control the blood glucose level of T2DM patients with HP positive gastroparesis, improve gastrointestinal function, reduce the level of serum inflammatory factors, and enhance the clinical effect of gastroparesis.
Keywords: type 2 diabetes; Helicobacter pylori; gastroparesis; mosapride citrate; anti HP infection therapy; gastrointestinal function; inflammatory factors